Antonio Luna MD, Presenter: Nothing to Disclose

Joan C. Vilanova MD, PhD, Abstract Co-Author: Nothing to Disclose

Sandra Baleato Gonzalez MD, Abstract Co-Author: Nothing to Disclose

Roberto Garcia Figueiras MD, Abstract Co-Author: Nothing to Disclose

Mariano Volpacchio MD, Abstract Co-Author: Nothing to Disclose

Christine O. Menias MD, Abstract Co-Author: Nothing to Disclose

Highlight the complementary role of these techniques in the detection and staging of different body tumors Review which of these techniques is more adequate for common clinical scenarios in oncology

1. Introduction 2. Staging - WB-DWI vs PET-CT - N-staging - M-staging: liver, brain, lung and bone metastases - Performance in staging of NSCLC, breast cancer, prostate cancer, malignant melanoma, colorectal cancer, lymphoma, multiple myeloma and others 3. Therapy monitoring 4. Prediction of treatment response 5. Postreatment surveillance 6. Conclusions

http://abstract.rsna.org/uploads/2014/14016665/14016665_1wi2.pdf

Luna, A, Vilanova, J, Baleato Gonzalez, S, Garcia Figueiras, R, Volpacchio, M, Menias, C, DWI vs 18-FDG PET/CT: Which Technique for Which Clinical Scenario?  [ MI Scavenger Hunt! ].  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14016665.html